Short answer
Inhibrx Biosciences, Inc. (INBX) filed an 8-K current report with the SEC on July 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure). Oxford facility expanded to $500.0 million, increasing potential liquidity for Inhibrx Biosciences.
Inhibrx Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Oxford facility expanded to $500.0 million, increasing potential liquidity for Inhibrx Biosciences
- $100.0 million Term C Loan funded immediately as gross proceeds
- Additional Term D borrowing capacity up to $225.0 million, subject to lender discretion
- Term C warrants cover 21,457 shares at $93.21 exercise price, creating potential dilution
- Company pledged all equity interests in Poplar Therapeutics as collateral for expanded financing
Item 2.03 · Creation of a Direct Financial Obligation
- Second Amendment to Oxford Loan Agreement creates or modifies a direct financial obligation
- Investor focus: revised debt terms, repayment requirements, and potential liquidity impact disclosed under Item 1.01
Item 3.02 · Unregistered Sales of Equity Securities
- Warrants issued to lenders as partial consideration for Term C Loan availability and funding
- Unregistered issuance relied on private-placement exemptions under Section 4(a)(2) and Rule 506 of Regulation D
- Accredited lender participation limits immediate resale, but warrants may create future equity dilution
- Investors should review Item 1.01 for warrant count, exercise price, expiration and Term C Loan obligations
Item 7.01 · Regulation FD Disclosure
- July 15, 2026 announcement: Second Amendment to Credit Facility and issuance of Term C Warrants
- Potential access to an additional $225.0 million under the Credit Facility, improving near-term financing flexibility
- Financing supports ongoing clinical development and future therapeutic-candidate data readouts
- Capital availability remains conditional, with execution and funding risks tied to clinical progress and financing markets
Item EX-99.1 · Exhibit EX-99.1
- Credit facility expanded to $500.0 million from $175.0 million previously drawn
- $100.0 million Term C tranche funded immediately, supporting continued clinical development
- Additional Term D borrowing capacity of up to $225.0 million remains subject to lender discretion
- 21,457 warrants issued at $93.21 per share, creating potential equity dilution over 10 years
- Increased liquidity extends funding flexibility for ozekibart and INBRX-106 ahead of data readouts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibrx Biosciences, Inc. 8-K filings
Get the next INBX 8-K as it lands
Follow INBX for push alerts, or ask the research agent what this filing means.